Immunotherapies are changing the landscape of cancer therapeutics, but currently around 80% of patients with solid tumors don’t respond to them. One reason for this is the existence of microenvironment barriers to immune infiltration. These can lead to immune excluded tumors, which can affect up to 3 million patients per year.
During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost discussed with Pedro Correa de Sampaio, Chief Executive Officer at Neobe Therapeutics, about the challenges to remove immunosuppressive constraints that prevent the infiltration of immune cells in a subset of cancers.
